Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Radiation Driven Alterations in Cell Cycle Progressions

FY 2024-25

Summary
Mitosis (M) is the shortest and most delicate phase of the cell cycle, especially following radiation therapy (RT). The G2-M checkpoint is in place to protect the cell from committing to mitosis when active DNA damage is present. However, this damage propagates into mitosis following RT and causes chromosome missegregation errors leading to whole genome instability and cytokine production. Our lab has previously shown that RT induces epigenetic changes that affect the assembly of the mitotic apparatus, and that mitotic errors can cause release of cytoplasmic DNA into the cytoplasm and subsequently RT-induced cytokine signaling. This latter influence alters the tumour microenvironment that impacts both tumour cure and progression. This project will test the hypothesis that disruption of both the G2-M checkpoint and epigenetic features are ultimately the cause of RT-induced mitotic errors, and that targeting these responses can enhance RT-based cell killing for therapeutic gain. I have developed several tools for this project including reliable cell synchronization methods to enrich mitotic cells and a high-throughput framework to track mitotic errors. We will integrate these methods with small molecule screening libraries for both epigenetic and cell cycle factors to identify whether specific modifications control chromosome segregation during the RT response. I will also determine how these RT-drug combinations impact cytokine production and cell survival. This project will provide new insight into how RT-induced damage persists past G2-M and manifests into mitotic defects, driving typical cancer phenotypes. I anticipate these studies will uncover new therapeutic interventions that manipulate molecular features of mitosis for improvements in patient response to RT.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529674
Name
Giglio Vanessa B
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Radiation Driven Alterations in Cell Cycle Progressions
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chromosome Missegregation; Cytokine Signaling; Dna Methylation; Epigenetic Modifications; G2-M Checkpoint; Genomic Instability; Mitosis; Mitotic Fidelity; Radiation Therapy; Radiosensitivity
Abstract
Mitosis (M) is the shortest and most delicate phase of the cell cycle, especially following radiation therapy (RT). The G2-M checkpoint is in place to protect the cell from committing to mitosis when active DNA damage is present. However, this damage propagates into mitosis following RT and causes chromosome missegregation errors leading to whole genome instability and cytokine production. Our lab has previously shown that RT induces epigenetic changes that affect the assembly of the mitotic apparatus, and that mitotic errors can cause release of cytoplasmic DNA into the cytoplasm and subsequently RT-induced cytokine signaling. This latter influence alters the tumour microenvironment that impacts both tumour cure and progression. This project will test the hypothesis that disruption of both the G2-M checkpoint and epigenetic features are ultimately the cause of RT-induced mitotic errors, and that targeting these responses can enhance RT-based cell killing for therapeutic gain. I have developed several tools for this project including reliable cell synchronization methods to enrich mitotic cells and a high-throughput framework to track mitotic errors. We will integrate these methods with small molecule screening libraries for both epigenetic and cell cycle factors to identify whether specific modifications control chromosome segregation during the RT response. I will also determine how these RT-drug combinations impact cytokine production and cell survival. This project will provide new insight into how RT-induced damage persists past G2-M and manifests into mitotic defects, driving typical cancer phenotypes. I anticipate these studies will uncover new therapeutic interventions that manipulate molecular features of mitosis for improvements in patient response to RT.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Giglio, Vanessa B
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~